Suggestions
Idioma
Guide for authors
Searcher
Journal Information
Cite
Cite
Share
Download PDF
More article options
Visits
129
Clinical Case
Available online 3 August 2026

Case report of CRIA syndrome: progression from initial response to anakinra to sustained control with tocilizumab

A propósito de un caso: síndrome de CRIA. Evolución desde la respuesta inicial a anakinra hasta el control sostenido con tocilizumab
Visits
129
Judith Hernández Sánchez
Corresponding author
judithreuma@gmail.com

Corresponding author.
, Doryan José García Olivas, Sergio Machín García, José Ángel Hernández Beriain
Servicio de Reumatología, Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Abstract

We present the case of a 40-day-old female infant with acute febrile illness, cutaneous lesions, severe respiratory distress, and shock refractory to antibiotic therapy. Skin biopsy revealed findings consistent with acute febrile neutrophilic dermatosis (Sweet syndrome). After excluding infectious, hematological, and hemophagocytic etiologies, an autoinflammatory syndrome was suspected, and treatment with anakinra and glucocorticoids was initiated, resulting in initial clinical improvement. However, after one year of treatment and dose tapering, the patient experienced relapses. Tocilizumab was then started, leading to a sustained clinical response to date.

Keywords:
CRIA syndrome
RIPK1
Autoinflammatory diseases
Anakinra
Tocilizumab
Pediatrics
Systemic inflammation
Resumen

Se presenta el caso de una paciente de 40 días de vida con cuadro febril agudo, lesiones cutáneas, insuficiencia respiratoria grave y shock refractario al tratamiento antibiótico. La biopsia cutánea orientó hacia dermatosis neutrofílica febril aguda tipo síndrome de Sweet. Tras la exclusión de etiología infecciosa, hematológica y síndrome hemofagocítico, se planteó un síndrome autoinflamatorio, iniciándose tratamiento con anakinra y glucocorticoides, con mejoría clínica inicial. Sin embargo, tras un año de tratamiento y posterior desescalada, la paciente presentó recaídas, por lo que se inició tocilizumab, observándose una respuesta clínica sostenida hasta la actualidad.

Palabras clave:
Síndrome CRIA
RIPK1
Enfermedades autoinflamatorias
Anakinra
Tocilizumab
Pediatría
Inflamación sistémica

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to
Reumatología Clínica (English Edition)
Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
Email
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools